Flagship Pioneering, LLC MRNA — MODERNA INC

Ownership history in Flagship Pioneering, LLC  ·  30 quarters on record

AI Ownership Summary

Flagship Pioneering, LLC reported MODERNA INC (MRNA) in 30 quarterly 13F filings from 2023 Q4 through 2026 Q1. Peak portfolio weight reached 72.53% in 2023 Q4. The latest visible filing shows MRNA at 20.26% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this MRNA ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Flagship Pioneering, LLC's position in MODERNA INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

MRNA was reported at 20.26% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
72.53% in 2023 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

MRNA stock page Flagship Pioneering, LLC fund profile Flagship Pioneering, LLC full holdings
How Flagship Pioneering, LLC held MRNA — position size vs. price
% of Fund (quarterly)    MRNA price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 10 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 UNCHANGED — — — 4,632,149 — 0% 20.26% $235.3M 2026-05-15 $49.04
2025 Q4 UNCHANGED — — — 4,632,149 — 0% 42.16% $136.6M 2026-02-17 $43.93
2025 Q3 UNCHANGED — — — 4,632,149 — 0% 40.89% $119.6M 2025-11-14 $24.77
2025 Q2 UNCHANGED — — — 4,632,149 — 0% 47.60% $127.8M 2025-08-14 $26.69
2025 Q1 UNCHANGED — — — 4,632,149 — 0% 55.70% $131.32B 2025-05-15 $23.65
2024 Q4 UNCHANGED — — — 4,632,149 — 0% 57.63% $192.60B 2025-02-14 $32.99
2024 Q3 UNCHANGED — — — 4,632,149 — 0% 52.30% $309.6M 2024-11-14 $39.77
2024 Q2 REDUCED 52.1% -43.7% ✅ 4,632,149 -5,033,889 -52.1% 65.22% $550.1M 2024-08-14 $82.25
2024 Q1 UNCHANGED — — — 9,666,038 — 0% 67.56% $1.03B 2024-05-15 $129.06
2023 Q4 UNCHANGED — — — 9,666,038 — 0% 72.53% $961.3M 2024-02-14 $85.95
20 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding MRNA

As of 2026 Q1 — sorted by position size

Merck & Co., Inc. 33.56% Theleme Partners LLP 3Y 7Y 27.24% Step Capital Management Pte. Ltd. 13.15% Mount Capital Ltd 3Y 8.09% PLUSTICK MANAGEMENT LLC 3Y 5.4% Telemark Asset Management, LLC 3Y 7Y 2.35% Affinity Asset Advisors, LLC 3Y 2.1% Artia Global Partners LP 3Y 2.03% Green Alpha Advisors, LLC 3Y 1.72% Collar Capital Management, LLC 1.63%

FAQ About Flagship Pioneering, LLC and MRNA

These are the practical questions this page is built to answer before you even open the full history table.

How long has Flagship Pioneering, LLC reported owning MRNA?

Flagship Pioneering, LLC reported MRNA across 10 quarterly 13F filings, from 2023 Q4 through 2026 Q1.

What was the largest reported MRNA position in Flagship Pioneering, LLC's portfolio?

The largest reported portfolio weight for MRNA was 72.53% in 2023 Q4.

What is the latest reported MRNA position on this page?

The most recent filing on this page is 2026 Q1, when Flagship Pioneering, LLC reported 4,632,149 shares, equal to 20.26% of portfolio, with an estimated market value of $235.3M.

What does the chart on this MRNA ownership page compare?

The chart compares Flagship Pioneering, LLC's quarterly MRNA portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Flagship Pioneering, LLC time their MRNA position?

Based on 13F filing dates vs. subsequent MRNA price moves, Flagship Pioneering, LLC correctly timed 3 out of 9 reported position changes (33%). The annualised alpha on MRNA relative to SPY over the holding period was -1.7%.

← Back to Flagship Pioneering, LLC Holdings